Patents news from FiercePharma
News
Sanofi's Lovenox patents 'unenforceable'
Will the way soon be clear for a generic form of Lovenox? Sanofi-Aventis just lost a bid to save its Read more...
New Canadian rules to delay big generics
Generics makers are up in arms over proposed patent rules in Canada. The drug copycats say the rules will delay generic Lipitor and several other blockbusters by as much as two years. (Can you hear Read more...
Roche appeals Mircera injunction
Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...
Dems back compulsory licensing
Now Rep. Henry Waxman and 26 of his Congressional Read more...
SPOTLIGHT: Thais to make their own generics
After announcing that it would bust the patents on four cancer meds, Thailand now says it's building a plant to make local versions of several anti-AIDS meds and the heart drug Clopidogrel. The Read more...
Novartis, Novo sue Bayer over patent
Novartis and Novo Nordisk are ganging up on Bayer, alleging that the German company's hemophilia treatment Kogenate infringes on one of their joint patents. In a statement, Bayer said it would Read more...
Fearing sanction, Thais may pay for drugs
Thailand may be running scared. Remember, the new health minister promised last week to review the country's compulsory licenses--which essentially break patent rules so that cheap meds can be had Read more...
Can Novartis drug fill Gleevec's shoes?
It's a good-news, bad-news sort of day for Novartis' cancer drugs. First, the good news: Tasigna won European Union approval for treatment of chronic myeloid leukemia. A potential follow-up to Read more...
Analyst: AZ "worst performer" in pharma
So, Dresdner Kleinwort, tell us how you really feel about AstraZeneca. The investment bank, which just started covering AstraZeneca's stock, minced no words in its first report. The company's in Read more...
FDA hands Crestor a fighting chance
In the battle of the cholesterol meds, Crestor just got a new weapon. The FDA approved AstraZeneca's application to market the drug not just for lowering cholesterol, but to treat hardening of the Read more...
Get more Patents coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight